Intellia Therapeutics Inc’s recent filing unveils that its VP, Chief Accounting Officer Dube Michael P unloaded Company’s shares for reported $38248.0 on Oct 02 ’24. In the deal valued at $19.01 per share,2,012 shares were sold. As a result of this transaction, Dube Michael P now holds 47,012 shares worth roughly $0.66 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Clark Eliana sold 405 shares, generating $9,287 in total proceeds. Upon selling the shares at $22.93, the EVP, Chief Technical Officer now owns 71,470 shares.
Before that, Verwiel Frank sold 1,505 shares. Intellia Therapeutics Inc shares valued at $37,625 were divested by the Director at a price of $25.00 per share. As a result of the transaction, Verwiel Frank now holds 17,948 shares, worth roughly $0.25 million.
Goldman downgraded its Intellia Therapeutics Inc [NTLA] rating to a Neutral from a a Buy in a research note published on February 23, 2024; the price target was decreased to $32 from $136. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in mid February with a ‘”a Peer perform”‘ rating. Canaccord Genuity began covering NTLA with “Buy” recommendation on April 13, 2023. Bernstein started covering the stock on March 21, 2023. It rated NTLA as “an Outperform”.
Price Performance Review of NTLA
On Tuesday, Intellia Therapeutics Inc [NASDAQ:NTLA] saw its stock fall -0.28% to $14.13. Over the last five days, the stock has lost -15.14%. Intellia Therapeutics Inc shares have fallen nearly -53.66% since the year began. Nevertheless, the stocks have fallen -49.75% over the past one year. While a 52-week high of $34.87 was reached on 02/29/24, a 52-week low of $13.54 was recorded on 11/18/24. SMA at 50 days reached $18.40, while 200 days put it at $23.24.
Levels Of Support And Resistance For NTLA Stock
The 24-hour chart illustrates a support level at 13.83, which if violated will result in even more drops to 13.54. On the upside, there is a resistance level at 14.34. A further resistance level may holdings at 14.56. The Relative Strength Index (RSI) on the 14-day chart is 34.87, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.34, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 86.25%. Stochastics %K at 9.65% indicates the stock is a buying.
How much short interest is there in Intellia Therapeutics Inc?
A steep rise in short interest was recorded in Intellia Therapeutics Inc stocks on 2024-10-31, growing by 1.01 million shares to a total of 16.15 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 15.14 million shares. There was a rise of 6.25%, which implies that there is a positive sentiment for the stock.
